Effects of Logacer in patients with chronic brain ischemia and moderate cognitive impairment: results of non-interventional clinical observation

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-8447-3264

Authors:

Zaharov V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(6): 93‑99

DOI: 10.17116/jnevro202212206193

Downloaded: 47

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zaharov VV. Effects of Logacer in patients with chronic brain ischemia and moderate cognitive impairment: results of non-interventional clinical observation. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(6):93‑99. (In Russ.)
https://doi.org/10.17116/jnevro202212206193

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Close metadata

OBJECTIVE

To assess the degree of satisfaction of outpatient neurologists with the results of therapy with Logacer 4 ml/1000 mg IM once daily in patients with chronic cerebral ischemia (CCI) and moderate cognitive impairment (MCI) in routine clinical practice.

MATERIAL AND METHODS

The study involved 7777 patients with chronic cerebral ischemia aged 55—75 years. All patients had moderate cognitive impairment according to the MMSE scale. The patients were prescribed injection therapy with Logacer 4 ml/1000 mg 1 r/day IM for 10 days. Patient satisfaction and adherence to therapy was assessed using the Likert scale.

RESULTS

At the indicated doses, Logacer caused a pronounced positive effect on the neurological status and cognitive functions of patients with CCI and MCI. 3733 (49%) patients rated their satisfaction with the therapy with Logacer 3323 (43%) as 5 points — 4 points. 3988 (52%) patients rated adherence to therapy with Logacer at 5 points, 3261 (43%) patients — at 4 points.

CONCLUSION

The drug Logacer is characterized by high effectiveness and good tolerability in patients with CCI.

Keywords:

chronic brain ischemia

moderate cognitive impairment

choline alfoscerate

Logacer

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-8447-3264

Received:

04.05.2022

Accepted:

16.05.2022

List of references:

https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689-701. https://doi.org/10.1016/S1474-4422(10)70104-6
Damulin IV, Parfenov VA, Skoromets AA, Yakhno NN. Circulatory disorders in the brain and spinal cord. In the book: Diseases of the nervous system. A Guide for Physicians. Yakhno N.N., Shtulman D.R. (ed.). M.: Medicine; 2019. (In Russ.).
Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12(5):483-486.
Cuadrado-Godia E, Dwivedi P, Sharma S, et al. Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies. J Stroke. 2018;20(3):302-320. https://doi.org/10.5853/jos.2017.02922
Kulesh AA, Emelin AYu, Bogolepova AN, et al. Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral ischemia) at an early (predemental) stage. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):4-12. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1-4-12
Erkinjuntti T, Roman G, Gauthier S, et al. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35:1010-1017. https://doi.org/10.1161/01.STR.0000120731.88236.33
Burchinsky SG. Possibilities of cholinergic pharmacotherapy in chronic cerebral ischemia. NeuroNews. 2019;9(110):34-38. (In Russ.).
Antipenko EA, Belyakov KM, Gustov AV. Modern possibilities for improving the functioning of the brain in conditions of chronic ischemia. breast cancer. RMZH. Neurology. 2016;7:445-447. (In Russ.).
Putilina MV. Personalized choice of drugs — choline precursors from the standpoint of evidence-based medicine. J Neurol Psychiatry. S.S. Korsakov. 2020;120(6):144-151. (In Russ.).
Muratorio A, Bonuccelli U, Nuti A, et al. A neurotropic approach to the treatment of multi-infarct dementia using l-a-glycerylphosphorylcholine. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2016;(2):53-60.
Batysheva TN, Nesterova OS, Otcheskaya OV, et al. The use of Cereton in patients with moderate cognitive disorders of vascular origin. Difficult Patient. 2009;4(5):42-47. (In Russ.).
Barbagallo Sangiorgi G, Barbagallo M, Giordano M, et al. Alpha Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann NY Acad Sci. 1994;717:253-269. https://doi.org/10.1111/j.1749-6632.1994.tb12095.x
Odinak MM, Voznyuk IA, Piradov MA, et al. Multicentre (pilot) study of the efficacy of gliatilin in acute ischemic stroke. Clinical Neurology. 2010;4(1):20-27. (In Russ.).
Parnetti L, Amenta F, Galla V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms Ageing Develop. 2001;122(16):2041-2055. https://doi.org/10.1016/s0047-6374(01)00312-8
El-Saifi N. Medication Adherence in Older Patients with Dementia: A Systematic Literature Review. J Pharm Pract. 2017;31(3):322-334. https://doi.org/10.1177/0897190017710524
Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6
Likert R. A technique for measurement of attitudes. Arch Psychol. 1932;140:5-55.

Close metadata